Effect of high dose vitamin C on Epstein-Barr viral infection

Nina Mikirova1, Ronald Hunninghake1

  • 1Bio-Communication Research Institute, Riordan Clinic, Wichita, USA.

Insights

High-dose intravenous vitamin C therapy may reduce Epstein-Barr virus (EBV) antibody levels and disease duration. This study found correlations between vitamin C, vitamin D, and EBV antibody levels in patients with chronic fatigue syndrome and mononucleosis.

Area of Science:

  • * Integrative Medicine
  • * Nutritional Biochemistry
  • * Viral Immunology

Background:

  • * Investigating natural compounds for antiviral properties is crucial.
  • * Epstein-Barr virus (EBV) is a common human pathogen associated with various illnesses.
  • * Chronic fatigue syndrome (CFS) and mononucleosis are often linked to EBV reactivation.

Purpose of the Study:

  • * To analyze the effect of high-dose intravenous vitamin C on EBV infection markers.
  • * To explore correlations between vitamin C, vitamin D, and EBV antibody levels.
  • * To assess the impact of therapy on disease duration in EBV-positive patients.

Main Methods:

  • * Retrospective analysis of patient data from the Riordan Clinic (1997-2006).
  • * Inclusion of 178 patients with elevated EBV EA IgG and 40 with elevated EBV VCA IgM.
  • * Intravenous vitamin C infusions ranged from 7.5 g to 50 g.

Main Results:

  • * High-dose intravenous vitamin C therapy showed a positive effect on reducing EBV antibody levels (EBV EA IgG and EBV VCA IgM).
  • * An inverse correlation was observed between plasma vitamin C levels and EBV VCA IgM in patients with mononucleosis and CFS.
  • * Higher vitamin D levels correlated with lower EBV EA IgG levels.

Conclusions:

  • * Intravenous vitamin C therapy appears to reduce EBV EA IgG and EBV VCA IgM antibody levels.
  • * Findings support in vitro observations that high ascorbate levels can hinder viral replication.
  • * Further clinical research into ascorbic acid for EBV infection is warranted.